Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest…
Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in…
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer…
The president of the Investment Office of the Presidency of the Republic of Turkey, Burak Dağlıoğlu, outlines the country’s current economic situation after posting the second-highest GDP growth among G20…
Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing…
Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies…
Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success…
Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for…
İsmail Yormaz, Recordati’s VP and regional director for south-east, highlights how the Milan-based company has become a shining example of a successful localization strategy, upcoming launches and investments, as well…
Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the…
Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how…
TITCK is the regulatory agency in charge of ensuring the safety of medicines, health products, cosmetics, and personal care products in Turkey. Its recently appointed president, Dr Tolga Karakan, discusses…
See our Cookie Privacy Policy Here